Survodutide: Research & Studies

Research Overview#

Survodutide (BI 456906) has been evaluated in two key Phase 2 clinical trials that form the basis of the current evidence: the COURAGE trial in obesity and a Phase 2b trial in MASH. These trials provided the dose-finding and efficacy signals that supported progression to the Phase 3 ACHIEVE clinical program. While the results have generated significant scientific interest, the evidence base is currently limited to Phase 2 data with relatively small sample sizes and shorter treatment durations compared to the extensive Phase 3 programs that support approved metabolic therapies.

The evidence level for survodutide is classified as moderate based on positive results from well-designed Phase 2 randomized controlled trials, with Phase 3 confirmation pending.

COURAGE Trial (Obesity - Phase 2)#

The COURAGE trial was the pivotal dose-finding study for survodutide in obesity. It was a Phase 2, randomized, double-blind, placebo-controlled trial conducted at multiple centers globally.

Study Design#

The trial enrolled 387 adults with overweight or obesity (BMI 28 or greater) without type 2 diabetes. Participants were randomized to one of four survodutide dose groups (0.6 mg, 2.4 mg, 3.6 mg, or 4.8 mg administered once weekly by subcutaneous injection, with dose escalation for the higher-dose groups) or placebo for 46 weeks. The primary endpoint was percent change in body weight from baseline to week 46.

Key Efficacy Results#

The COURAGE trial demonstrated a clear dose-dependent relationship between survodutide dose and weight loss. At the highest evaluated dose (4.8 mg weekly), survodutide achieved a mean body weight reduction of approximately 14.9% from baseline at week 46, compared to 2.8% with placebo. The treatment difference of approximately 12.1 percentage points was statistically significant (p<0.001).

Results across all dose groups demonstrated the dose-response pattern:

Cardiometabolic Outcomes#

Beyond weight loss, survodutide treatment was associated with improvements in multiple cardiometabolic risk factors. These included dose-dependent reductions in waist circumference, improvements in triglyceride and non-HDL cholesterol levels, reductions in high-sensitivity C-reactive protein (a marker of systemic inflammation), and stable or improved glycemic parameters (blood glucose and HbA1c levels).

The preservation of glycemic homeostasis across dose groups was a particularly important finding, as it confirmed that the GLP-1R component of survodutide adequately counterbalanced the glucose-raising tendency of glucagon receptor activation. This validation of the dual agonist concept was central to the rationale for Phase 3 progression.

Treatment-Free Follow-Up#

Extended data from a 16-week treatment-free follow-up period after the 46-week active treatment phase showed partial weight regain after survodutide discontinuation. This finding is consistent with observations from other incretin-based therapies, including semaglutide (STEP-1 extension) and tirzepatide (SURMOUNT-4), and supports the chronic disease model of obesity treatment in which ongoing therapy is likely necessary to maintain weight loss.

Safety Summary#

The most common adverse events were gastrointestinal (nausea, vomiting, diarrhea, constipation), occurring predominantly during dose escalation and at higher doses. Treatment discontinuation due to adverse events occurred in approximately 10-15% of patients in the higher-dose groups versus approximately 4% with placebo. Heart rate increases of 2-6 beats per minute were observed. No confirmed cases of pancreatitis occurred. These safety findings informed the design of Phase 3 trials with optimized dose escalation schedules.

Phase 2b MASH Trial#

The MASH trial represented a targeted evaluation of survodutide's hepatic effects, leveraging the glucagon receptor component's known role in promoting hepatic lipid oxidation and reducing steatosis.

Study Design#

The trial enrolled 293 patients with biopsy-confirmed MASH and liver fibrosis stages F1-F3. Participants were randomized to survodutide (2.4 mg, 4.8 mg, or 6.0 mg weekly, with dose escalation) or placebo for 48 weeks. The primary endpoint was histological improvement assessed by paired liver biopsies at baseline and week 48.

Histological Outcomes#

The results demonstrated clinically meaningful histological improvements. In the 4.8 mg group, 47% of patients achieved MASH resolution without worsening of fibrosis, compared to 14% with placebo (p<0.001). This approximately 33-percentage-point treatment difference represents a substantial effect on a histological endpoint that has been challenging for previous therapeutic approaches.

Improvement in liver fibrosis by at least one stage was observed in 36% of the 4.8 mg group versus 22% with placebo. While the fibrosis improvement was more modest than the steatohepatitis resolution, any improvement in fibrosis staging is considered clinically meaningful given the relationship between fibrosis progression and long-term liver outcomes.

Imaging and Biomarker Outcomes#

Survodutide produced substantial reductions in liver fat content as measured by MRI-based proton density fat fraction (MRI-PDFF). The 4.8 mg dose group showed a mean relative reduction in liver fat of approximately 64% from baseline, compared to approximately 6% with placebo. This magnitude of liver fat reduction is among the largest reported for any pharmacotherapy in MASH and reflects the direct hepatic lipid-mobilizing effects of glucagon receptor agonism.

Serum alanine aminotransferase (ALT) levels, a widely used biomarker of hepatocellular injury, improved significantly across all survodutide dose groups. ALT normalization suggests reduced hepatocellular damage and is consistent with the histological improvements observed on biopsy.

Mechanistic Significance#

The MASH trial results are scientifically noteworthy because they provide clinical evidence supporting the hypothesis that glucagon receptor agonism provides direct hepatic benefits beyond what is achievable through weight loss alone. While weight loss from any intervention reduces hepatic steatosis, the magnitude and rapidity of liver fat reduction observed with survodutide suggest that glucagon-mediated hepatic lipid oxidation contributes an additional, direct hepatic effect.

This mechanistic differentiation is potentially important for the clinical positioning of survodutide relative to agents that lack glucagon receptor activity, such as semaglutide and tirzepatide, particularly in the MASH indication.

Preclinical Research#

Preclinical studies in animal models of obesity and metabolic disease provided the foundational evidence for survodutide's dual agonist approach.

Diet-Induced Obesity Models#

Studies in diet-induced obese (DIO) mice demonstrated that dual GLP-1/glucagon receptor agonists produced greater weight loss than equipotent doses of either single-receptor agonist alone. Crucially, the dual agonist approach preserved lean body mass while preferentially reducing fat mass, a finding attributed to the glucagon-driven increase in energy expenditure that is absent with GLP-1 agonist monotherapy.

Energy Expenditure Studies#

Preclinical and early clinical studies of glucagon receptor activation demonstrated increases in resting energy expenditure of approximately 100-200 kcal/day. This thermogenic effect, mediated through hepatic mitochondrial oxidative phosphorylation and futile cycling, represents a mechanistically distinct pathway for weight reduction compared to the caloric intake reduction achieved through GLP-1R-mediated appetite suppression.

Hepatic Lipid Metabolism#

Glucagon receptor activation in preclinical models stimulated hepatic fatty acid beta-oxidation, increased ketogenesis, and reduced hepatic de novo lipogenesis and VLDL secretion. These hepatic effects provided the mechanistic rationale for evaluating survodutide in MASH.

Phase 3 ACHIEVE Program#

Based on the Phase 2 results, Boehringer Ingelheim initiated the Phase 3 ACHIEVE clinical program. This program is expected to include:

• ACHIEVE-1: Evaluation of survodutide for weight loss in adults with obesity or overweight without type 2 diabetes. This trial will provide pivotal efficacy data for the obesity indication.
• MASH trials: Multiple trials evaluating histological endpoints in patients with MASH, building on the Phase 2b results.
• Expanded dose evaluation: Doses up to 6.0 mg weekly with optimized titration schedules designed based on Phase 2 tolerability experience.

The Phase 3 program will generate the evidence needed for regulatory submissions to the FDA and EMA. Until Phase 3 results are available, the efficacy conclusions from Phase 2 data should be considered preliminary.

Evidence Quality Assessment#

The current evidence base for survodutide is classified as moderate quality, reflecting the following assessment:

The evidence level will be reassessed following the availability of Phase 3 data from the ACHIEVE program.

Key Research Gaps#

Several important research questions remain unanswered:

1. Phase 3 confirmation: All efficacy conclusions are based on Phase 2 data. The ACHIEVE program will determine whether the Phase 2 signals are confirmed in larger, longer-duration pivotal trials with more diverse patient populations.

2. Comparative effectiveness: No head-to-head trials with any approved therapy have been conducted. Cross-trial comparisons are inherently limited, and direct comparative data are needed to establish the relative clinical positioning of survodutide.

3. Cardiovascular outcomes: The long-term cardiovascular effects of dual glucagon/GLP-1 receptor agonism are unknown. Dedicated cardiovascular outcomes studies will be necessary to characterize the cardiovascular benefit-risk profile.

4. Long-term safety of glucagon agonism: Chronic glucagon receptor stimulation introduces pharmacological effects not present in approved GLP-1 receptor agonists. The long-term effects on hepatic function, alpha-cell dynamics, ketone body production, and metabolic homeostasis require extended safety monitoring.

5. Body composition: The effects of survodutide on lean body mass versus fat mass during weight loss require further characterization. Preclinical data suggest preferential fat mass reduction, but clinical confirmation in human studies is needed.

6. Type 2 diabetes population: A dedicated trial in patients with type 2 diabetes has not been conducted, and the glycemic efficacy and safety of survodutide in this population remain to be established.

7. Optimal dosing: The optimal dose, escalation schedule, and long-term maintenance strategy for survodutide have not been definitively established. The Phase 3 program will further refine these parameters.

Related Reading#

• Survodutide overview and research guide
• Survodutide dosing protocols
• Survodutide molecular structure